Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

INCR - Intercure Ltd


IEX Last Trade
2.28
0.050   2.193%

Share volume: 26,595
Last Updated: Fri 30 Aug 2024 04:42:50 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$2.23
0.05
2.24%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
7.58%
1 Month
4.61%
3 Months
-22.79%
6 Months
13.50%
1 Year
50.33%
2 Year
-56.09%
Key data
Stock price
$2.28
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.99 - $3.72
52 WEEK CHANGE
$0.46
MARKET CAP 
102.454 M
YIELD 
N/A
SHARES OUTSTANDING 
45.134 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.28
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$26,500
AVERAGE 30 VOLUME 
$35,011
Company detail
CEO:
Region: US
Website: intercure.co
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

intercure (dba canndoc) (nasdaq: incr) (tsx: incr.u) (tase: incr) is the leading, profitable, and fastest growing cannabis company outside of north america. canndoc, a wholly owned subsidiary of intercure, is israel’s largest licensed cannabis producer and one of the first to offer good manufacturing practices (gmp) certified and pharmaceutical-grade medical cannabis products. intercure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of north america. for more information, visit: http://www.intercure.co.

Recent news